Literature DB >> 30692216

Cognate Nonlytic Interactions between CD8+ T Cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties.

Roland G Stein1,2,3, Stefan Ebert1,2, Laura Schlahsa1, Claus J Scholz4,5, Matthias Braun3,6, Petra Hauck1,2, Evi Horn1, Camelia-Maria Monoranu7, Vincent J Thiemann1, Michael P Wustrow1, Sebastian F Häusler1, Itsaso Montalbán Del Barrio1, Tanja N Stüber1,3, Matthias Wölfl4, Johannes Dietl1, Andreas Rosenwald7,8, Joachim E Diessner1, Achim Wöckel1, Jörg Wischhusen9,2,3.   

Abstract

Targeting of tumor immune escape mechanisms holds enormous therapeutic potential. Still, most patients progress under immune checkpoint blockade and some even become hyperprogressors. To investigate how cancer cells respond to activated but ineffective T cells, we challenged peptide-loaded MCF-7 breast cancer cells with antigen-specific CD8+ T cells in which lytic granules had been destroyed by pretreatment with Concanamycin A. Gene expression analysis after coculture revealed simultaneous induction of PD-L1, IDO1, CEACAM1, and further immunoregulatory checkpoints in breast cancer cells. Strikingly, we further observed gene signatures characteristic for dedifferentiation and acquisition of pluripotency markers including Yamanaka factors. Cognate interaction with nonlytic CD8+ T cells also increased the proportion of stem cell-like cancer cells in a cell-to-cell contact- or (at least) proximity-dependent manner in various cell lines and in primary breast cancer cell cultures; this induction of stem cell-like properties was confirmed by enhanced tumor-forming capacity in immunodeficient mice. Resulting tumors were characterized by enhanced cell density, higher proliferation rates, and increased propensity for lymphoid metastasis. These findings describe a widely underappreciated pathway for immune escape, namely immune-mediated dedifferentiation of breast cancer cells, which is associated with profound changes in gene expression and cellular behavior. As the enhanced malignant potential of cancer cells after nonlytic cognate interactions with CD8+ T cells enables increased tumor growth and metastasis in BALB/cnu/nu mice, the described mechanism may provide a possible explanation for the clinical phenomenon of hyperprogression in response to unsuccessful immunotherapy. SIGNIFICANCE: This study shows that ineffective immune responses not only fail to clear a malignancy, but can also activate pathways in cancer cells that promote stemness and tumor-seeding capacity. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30692216     DOI: 10.1158/0008-5472.CAN-18-0387

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

2.  Resistance to Immunotherapy: Mechanisms and Means for Overcoming.

Authors:  Mohamad A Salkeni; John Y Shin; James L Gulley
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  IFN-γ and CD38 in Hyperprogressive Cancer Development.

Authors:  Stefania Angelicola; Francesca Ruzzi; Lorena Landuzzi; Laura Scalambra; Francesco Gelsomino; Andrea Ardizzoni; Patrizia Nanni; Pier-Luigi Lollini; Arianna Palladini
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

4.  Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy.

Authors:  Whitney Barham; Ruifeng Guo; Sean S Park; Joerg Herrmann; Haidong Dong; Yiyi Yan
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 7.561

Review 5.  Cancer Stemness Meets Immunity: From Mechanism to Therapy.

Authors:  Peiwen Chen; Wen-Hao Hsu; Jincheng Han; Yan Xia; Ronald A DePinho
Journal:  Cell Rep       Date:  2021-01-05       Impact factor: 9.423

Review 6.  Cancer stem cell-immune cell crosstalk in tumour progression.

Authors:  Defne Bayik; Justin D Lathia
Journal:  Nat Rev Cancer       Date:  2021-06-08       Impact factor: 60.716

Review 7.  Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses.

Authors:  Hongjing Zang; Jinwu Peng; Hongmei Zheng; Songqing Fan
Journal:  Front Oncol       Date:  2020-04-29       Impact factor: 6.244

Review 8.  Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets.

Authors:  Luise Müller; Antje Tunger; Ioana Plesca; Rebekka Wehner; Achim Temme; Dana Westphal; Friedegund Meier; Michael Bachmann; Marc Schmitz
Journal:  Front Immunol       Date:  2020-02-05       Impact factor: 7.561

Review 9.  Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model.

Authors:  Mikolaj Kocikowski; Katarzyna Dziubek; Maciej Parys
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639

10.  Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection.

Authors:  Ana Pires; Alexander Greenshields-Watson; Emma Jones; Andrew Godkin; Awen Gallimore; Kathryn Smart; Sarah N Lauder; Michelle Somerville; Stefan Milutinovic; Howard Kendrick; James P Hindley; Rhiannon French; Matthew J Smalley; William J Watkins; Robert Andrews
Journal:  Cancer Immunol Res       Date:  2020-10-06       Impact factor: 12.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.